Use of recombinant erythropoietin in a pregnant renal transplant recipient.
The use of recombinant human erythropoietin (rHuEPO) has been extensively studied among patients with anemia of chronic renal failure. Less well described is its safe use during pregnancy. We report a case of a 17-year-old gravid renal transplant patient with underlying renal insufficiency who became severely anemic and responded to rHuEPO. As the number of renal transplant recipients who become pregnant increases, the need for correction of anemia of chronic renal failure during pregnancy may rise as well. Our case illustrates the use of rHuEPO in this situation.
Thorp
M
M
St. Vincent's Medical Center, Portland, OR 97225, USA.
Pulliam
J
J
D000293:Adolescent; D000740:Anemia / Q000209:etiology / Q000628:therapy*; D003404:Creatinine / Q000097:blood; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D016030:Kidney Transplantation; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000097:blood / Q000628:therapy*; D011263:Pregnancy Trimester, Third; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin; D003404:Creatinine